Skip to content
OmniAb
  • About
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antibody Generation
      • Antigen Design
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmnidAb
      • OmniTaur
      • Bispecific Platforms
    • xPloration Screening
    • Antibody Optimization
      • Fc-Silencing Technology
    • Ion Channel and Transporter Technology
    • In Silico Technologies
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Financials
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Environment
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact
OmniAb
  • About
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antibody Generation
      • Antigen Design
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmnidAb
      • OmniTaur
      • Bispecific Platforms
    • xPloration Screening
    • Antibody Optimization
      • Fc-Silencing Technology
    • Ion Channel and Transporter Technology
    • In Silico Technologies
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Financials
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Environment
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact

OmniChicken® & OmniClic®: Transgenic chickens for human antibody discovery

  • Antibody Generation
  • Antigen Design
  • OmniRat
  • OmniMouse
  • OmniChicken
  • OmnidAb
  • OmniTaur
  • Bispecific Platforms

The only human Ig-transgenic chicken for the discovery of therapeutic antibodies

More than 300 million years of evolutionary distance drives divergence between mammalian and avian orthologs. Our genetically modified chicken, the OmniChicken® and OmniClic®, offer affinity matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to highly conserved therapeutic targets. When it comes to transgenic chicken production, OmniAb’s chicken antibody research supports work being done in laboratories across the United States.

Leverage the advantage of using distinct transgenic animals

Due to the large evolutionary distance between birds and mammals, many target antigens that are not immunogenic in rats or mice induce a strong antibody response in chickens. Indeed, scientists consider chickens to be an ideal host for generating antibodies against mammalian or human protein antigens. This insight has led to OmniAb’s ongoing work in transgenic chicken antibody research.

Chief advantages of using transgenic chicken antibodies include:

* Chickens react to mammalian genes as foreign, prompting a strong immune response desired by scientific researchers. This has resulted in increased demand in the lab for a validated genetically engineered chicken.

* Chicken antibodies are more stable than mammalian antibodies, with a longer shelf life when properly stored under climate control.

* You can produce higher signals during tests due to the bigger glycosylation index, enabling more HRP labeling.

Learn more about the OmniAb difference

About OmniChicken

Launched in 2016, OmniChicken is the first successfully genetically altered chicken with an immune system that can efficiently generate human sequence antibody repertoires.

OmniChicken features:

  • A high level of functional antibody diversity is achieved through the powerful in vivo diversification process of gene conversion.
  • Patented genetic design focuses diversity in the CDR regions while maintaining conserved and highly developable framework regions based on human VH3-23 and VK3-15 or VL1-44
  • OmniChicken antibodies bind to diverse epitopes on human targets with high affinity, and typically feature excellent developability profiles

About OmniClic: A transgenic chicken that generates bispecific antibodies

OmniClic transgenic chickens express a fixed VK3-15 light chain so different antibodies generated using this platform can be easily combined to form a bispecific human antibody.

Learn About OmniClic

Scientific Publications

Discovery of high affinity, pan-allelic, and panmammalian reactive antibodies against the myeloid checkpoint receptor SIRPα

Complementary epitopes and favorable developability of monoclonal anti-LAMP1 antibodies generated using two transgenic animal platforms

Questions about OmniChicken? Connect with OmniAb today

At OmniAb, we’re proud of our reputation in the transgenic research animals industry. We are the only company offering chickens made with transgenic technology, and we welcome any questions you might have. To discover how our OmniChicken can fit into your laboratory’s workflow, get in touch with us today.

About

  • Team
  • Board of Directors
  • Careers

Partnerships

  • Overview
  • Why Partner with OmniAb?
  • Partner Pipeline
  • Contact Business Development

Technology

  • Overview
  • Antigen Design
  • Antibody Generation
  • Antibody Optimization
  • Ion Channel and Transporter Technology
  • Scientific Publications

OmniAb, Inc.
5980 Horton Street
Suite 600
Emeryville, CA 94608

Contact | Privacy Policy | Disclaimer

© 2025 OmniAb, Inc. All rights reserved.